Inovio Pharmaceuticals announced a breakthrough in its ongoing research on novel drugs.
The company announced it has developed a novel compound in the human brain that blocks the brain’s excitatory neurons.
Inovios researchers believe that the compound could be used in a variety of treatments.
The compound was tested in patients with amyotrophic lateral sclerosis (ALS), a rare neurological disorder, and the company is developing it for treatment of Parkinson’s disease, which is a degenerative neurological disease.
According to Inovies chief executive officer, Thomas Killebrew, the compound blocks a class of brain cells known as excitotoxic, which are known to play a role in the development of neurodegenerative diseases.
These neurons are crucial to the formation of new neurons, and when these cells are not firing, the brain cannot function properly.
“We have developed a compound that blocks excitoxins that can be found in the brain.
And that compound is a new class of compound that we call inovios,” Killeburn said.
“That compound has the ability to block excitoxin in a way that we are only now beginning to understand.”
The compound, named inovial-1, has the potential to be used for treating ALS, Parkinson’s and other neurodegenative diseases, including Huntington’s disease.
Killeburg said the compound, which has been tested in mice and is in clinical trials, is also being tested for its ability to treat Huntington’s.
In the study, published in the journal Nature Neuroscience, researchers tested the compound in mice that had the disease.
In this study, the researchers used an animal model that had been engineered to be genetically susceptible to Huntington’s, a disease that affects about one in three people over the age of 65.
In addition to Huntington, the mice were also tested for a different type of Huntington’s called Huntington’s Progressive Defects, which affects about 3 percent of the population.
The disease affects about 4 percent of people over age 65.
The research was conducted by scientists from the University of Southern California, the University at Buffalo, and UCLA.
The study was funded by the U.S. National Institutes of Health.
The scientists say the compound they tested works in the body in three ways: 1.
It blocks excitation of excitochondria, the organelles that are made up of a group of mitochondria.
It prevents the formation and spread of toxic proteins called glyoxalase.
It allows the cell to store and utilize energy.
“The first step was to identify what the proteins were, and what the functions were,” Kinebrew said.
The researchers then began to investigate what excitogenic proteins are, what the enzymes are that make them, and where they were made, according to the study.
The protein called Glyoxalases was discovered in the 1970s.
Glyoxas were found in proteins called prolamins, which were proteins that were formed when the prolamin protein that was produced was removed from the cell, according the study on the Nature Neuroscience website.
The prolamines are thought to help keep cells in their correct position, which helps regulate the production of new mitochondria and cells that support them.
Kineburg said he was amazed by the finding.
“We were just so excited when we found this one.
It just really blew our minds,” he said.
Kines said the discovery could help in the discovery of new drugs.
In a statement, Killeberg said: “Our goal is to develop compounds that block the excitoxic activity of excitable cells in the CNS, as well as provide novel therapeutics for patients with these diseases.
Our aim is to create a new and exciting class of medicines that can address the many aspects of human health that are directly linked to our daily activities.”